Department of Family Medicine and Primary Care, The University of Hong Kong, Hong Kong, China
Department of Family Medicine and Primary Care, The University of Hong Kong, Hong Kong, China.
Diabetes Care. 2018 Jun;41(6):1134-1141. doi: 10.2337/dc17-2443. Epub 2018 Mar 28.
The objective of this study was to compare the incidence of cardiovascular disease (CVD) among patients with type 2 diabetes mellitus (T2DM) with treated hypertension who achieved systolic blood pressures (SBPs) of <120, <130, and <140 mmHg after an increase in their antihypertensive regimen.
A retrospective cohort study was conducted on 28,014 primary care adult patients with T2DM with no prior diagnosis of CVD and who achieved SBP readings <140 mmHg after an increase in the number of antihypertensive medications prescribed. Using an extension of propensity score matching, a total of 2,079, 10,851, and 15,084 matched patients with achieved SBP measurements of <120, <130, and <140 mmHg were identified. The association between achieved SBP and incident CVD were evaluated using Cox regressions. Subgroup analyses were conducted by stratifying patients' baseline characteristics.
Over a median follow-up period of 4.8 years, the incidence of CVD in patients with achieved SBP measures of <120, <130, and <140 mmHg were 318 (15.3%; incidence rate [IR] 34.3/1,000 person-years [PY]), 992 (9.1%; IR 20.4/1,000 PY), and 1,635 (10.8%; IR 21.4/1,000 PY). Achieved SBP <120 mmHg was associated with a higher risk of CVD compared with achieved SBP <130 mmHg (hazard ratio [HR] 1.75 [95% CI 1.53, 2.00]) and achieved SBP <140 mmHg (HR 1.67 [95% CI 1.46, 1.90]). There was a significant reduction in CVD risk in patients <65 years (HR 0.81 [95% CI 0.69, 0.96]) but no difference for other patients, including patients ≥65 years, who achieved SBP <130 mmHg when compared with the group that achieved SBP <140 mmHg.
Our findings support a SBP treatment target of 140 mmHg and suspect no risk reduction attenuation on CVD for lower SBP targets (<120 or <130 mmHg) for most patients with uncomplicated T2DM. A randomized control trial is still needed to confirm these findings.
本研究旨在比较接受降压治疗的 2 型糖尿病(T2DM)患者在增加降压药物后收缩压(SBP)降至<120、<130 和<140mmHg 时,心血管疾病(CVD)的发生率。
对 28014 例无 CVD 既往诊断且在增加降压药物后 SBP 读数<140mmHg 的 T2DM 成年初级保健患者进行回顾性队列研究。通过扩展倾向评分匹配,共确定了 2079、10851 和 15084 例 SBP 测量值分别<120、<130 和<140mmHg 的匹配患者。使用 Cox 回归评估达到 SBP 与 CVD 事件的相关性。通过分层患者的基线特征进行亚组分析。
中位随访时间为 4.8 年,SBP 测量值<120、<130 和<140mmHg 的患者中 CVD 的发生率分别为 318(15.3%;发病率[IR]为 34.3/1000人年[PY])、992(9.1%;IR 为 20.4/1000 PY)和 1635(10.8%;IR 为 21.4/1000 PY)。与 SBP<130mmHg 相比,SBP<120mmHg 与 CVD 风险升高相关(风险比[HR]1.75[95%CI 1.53,2.00])和 SBP<140mmHg(HR 1.67[95%CI 1.46,1.90])。在<65 岁的患者中,CVD 风险显著降低(HR 0.81[95%CI 0.69,0.96]),但对于其他患者,包括达到 SBP<130mmHg 的≥65 岁患者,与达到 SBP<140mmHg 的患者相比,没有降低 CVD 风险的差异。
我们的研究结果支持将 SBP 治疗目标设定为 140mmHg,并怀疑对于大多数无并发症的 T2DM 患者,较低的 SBP 目标(<120 或<130mmHg)对 CVD 风险降低没有减弱。仍需要随机对照试验来证实这些发现。